You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 589 RUBY trial post hoc analysis of number needed to treat and incremental costs per outcome of dostarlimab + carboplatin-paclitaxel (CP) vs placebo + CP for primary advanced/recurrent endometrial cancer

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Clinical Trial Completed
589 RUBY trial post hoc analysis of number needed to treat and incremental costs per outcome of dostarlimab + carboplatin-paclitaxel (CP) vs placebo + CP for primary advanced/recurrent endometrial cancer

 

Online download statistics by month:

Online download statistics by month: November 2023 to June 2025

AbstractFullPdf
Nov 2023168013
Dec 20235708
Jan 20245206
Feb 20245405
Mar 20243801
Apr 20245804
May 20242603
Jun 20245007
Jul 20244007
Aug 20242802
Sep 20244808
Oct 20244609
Nov 20244401
Dec 20241604
Jan 20254008
Feb 2025702
Mar 2025001
Apr 2025003
May 2025006
Jun 2025003
Total7720101